130 related articles for article (PubMed ID: 8790190)
21. Somatostatin receptor imaging in CNS tumours using 111In-octreotide.
Maini CL; Sciuto R; Tofani A; Ferraironi A; Carapella CM; Occhipinti E; Mottolese M; Crecco M
Nucl Med Commun; 1995 Sep; 16(9):756-66. PubMed ID: 7478408
[TBL] [Abstract][Full Text] [Related]
22. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
23. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
24. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers.
Kälkner KM; Janson ET; Nilsson S; Carlsson S; Oberg K; Westlin JE
Cancer Res; 1995 Dec; 55(23 Suppl):5801s-5804s. PubMed ID: 7493349
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin receptor scintigraphy in patients with pituitary adenoma.
Rieger A; Rainov NG; Elfrich C; Klaua M; Meyer H; Lautenschläger C; Burkert W; Mende T
Neurosurg Rev; 1997; 20(1):7-12. PubMed ID: 9085281
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.
Haldemann AR; Rösler H; Barth A; Waser B; Geiger L; Godoy N; Markwalder RV; Seiler RW; Sulzer M; Reubi JC
J Nucl Med; 1995 Mar; 36(3):403-10. PubMed ID: 7884502
[TBL] [Abstract][Full Text] [Related]
27. 111In-octreotide scintigraphy in oncology.
Krenning EP; Kwekkeboom DJ; Reubi JC; Van Hagen PM; van Eijck CH; Oei HY; Lamberts SW
Metabolism; 1992 Sep; 41(9 Suppl 2):83-6. PubMed ID: 1355591
[TBL] [Abstract][Full Text] [Related]
28. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
[TBL] [Abstract][Full Text] [Related]
29. Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis.
Kurtaran A; Raderer M; Müller C; Prokesch R; Kaserer K; Eibenberger K; Koperna K; Niederle B; Virgolini I
J Nucl Med; 1997 Jun; 38(6):880-1. PubMed ID: 9189133
[TBL] [Abstract][Full Text] [Related]
30. Adrenal glands imaging with indium-111-DTPA-D-Phe1-octreotide following ACTH therapy.
Lorberboym M; Rubin P; Warner R; Machac J
J Nucl Med; 1997 Sep; 38(9):1489-91. PubMed ID: 9293815
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide.
Schillaci O; Annibale B; Scopinaro F; delle Fave G; Colella AC
J Nucl Med; 1997 Jun; 38(6):886-7. PubMed ID: 9189135
[TBL] [Abstract][Full Text] [Related]
32. Pharyngeal pituitary non-functioning adenoma with normal intra-sellar gland: massive tumor shrinkage on octreotide therapy.
Pugnale N; Waridel F; Bouzourène H; Boubaker A; Pugnale M; Gaillard RC; Gomez F
Eur J Endocrinol; 2003 Mar; 148(3):357-64. PubMed ID: 12611618
[TBL] [Abstract][Full Text] [Related]
33. Indium-111-pentetreotide uptake in endocrine tumors and lymphoma.
Leners N; Jamar F; Fiasse R; Ferrant A; Pauwels S
J Nucl Med; 1996 Jun; 37(6):916-22. PubMed ID: 8683311
[TBL] [Abstract][Full Text] [Related]
34. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy.
Lipp RW; Silly H; Ranner G; Dobnig H; Passath A; Leb G; Krejs GJ
J Nucl Med; 1995 Jan; 36(1):13-8. PubMed ID: 7799065
[TBL] [Abstract][Full Text] [Related]
35. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide.
Andersson P; Forssell-Aronsson E; Johanson V; Wängberg B; Nilsson O; Fjälling M; Ahlman H
J Nucl Med; 1996 Dec; 37(12):2002-6. PubMed ID: 8970523
[TBL] [Abstract][Full Text] [Related]
36. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
Oppizzi G; Cozzi R; Dallabonzana D; Orlandi P; Benini Z; Petroncini M; Attanasio R; Milella M; Banfi G; Possa M
J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
[TBL] [Abstract][Full Text] [Related]
37. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
[TBL] [Abstract][Full Text] [Related]
38. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy.
Nilsson S; Reubi JC; Kalkner KM; Laissue JA; Horisberger U; Olerud C; Westlin JE
Cancer Res; 1995 Dec; 55(23 Suppl):5805s-5810s. PubMed ID: 7493350
[TBL] [Abstract][Full Text] [Related]
39. Indium-111-pentetreotide imaging in intra-axial brain tumors: comparison with thallium-201 SPECT and MRI.
Lee JD; Kim DI; Lee JT; Chang JW; Park CY
J Nucl Med; 1995 Apr; 36(4):537-41. PubMed ID: 7699438
[TBL] [Abstract][Full Text] [Related]
40. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Mure A; Plouin PF; Caillou B; Parmentier C
J Nucl Med; 1995 Jan; 36(1):1-6. PubMed ID: 7799058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
